Investors
- VOLUNTARY ANNOUNCEMENT - SECOND GENERATION OF HIGHLY-EFFECTIVE ABSORBED TETANUS VACCINE OBTAINED THE CLINICAL TRIAL APPROVAL
- 2024-12-19
- VOLUNTARY ANNOUNCEMENT - SUSPENSION CULTURE INFLUENZA VACCINE (MDCK CELLS) WITH NEW TECHNOLOGICAL ROUTE OBTAINED THE CLINICAL TRIAL APPROVAL
- 2024-12-19
- VOLUNTARY ANNOUNCEMENT - SUBMISSION OF THE PRE-APPLICATION FOR MARKETING REGISTRATION OF THE ITERATIVE SERUM-FREE RABIES VACCINE
- 2024-11-17
- VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF THE ITERATIVE-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE
- 2024-11-07
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
- 2024-11-04
- VOLUNTARY ANNOUNCEMENT - 13-VALENT PNEUMONIA CONJUGATE VACCINE PHASE III CLINICAL TRIALS COMPLETED, PRODUCTION LICENSE OBTAINED AND APPLICATION FOR DRUG MARKETING REGISTRATION DULY SUBMITTED
- 2024-10-31
- VOLUNTARY ANNOUNCEMENT - MRNA RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE OBTAINED THE CLINICAL TRIAL APPROVAL
- 2024-10-30
- VOLUNTARY ANNOUNCEMENT - UNBLINDING OF DATA FROM PHASE III CLINICAL TRIAL OF ITERATIVE SERUM-FREE RABIES VACCINE: PRE-DEFINED CLINICAL OBJECTIVES MET WITH GOOD IMMUNOGENICITY AND SAFETY
- 2024-10-06
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
- 2024-10-04
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
- 2024-09-03
- RE-DESIGNATION OF DIRECTORS
- 2024-08-29
- VOLUNTARY ANNOUNCEMENT - OFFICIAL APPLICATION FOR CLINICAL TRIALS FOR QUADRIVALENT INFLUENZA VIRUS VACCINE (MDCK CELLS) SUBMITTED
- 2024-08-29
- VOLUNTARY ANNOUNCEMENT - OFFICIAL APPLICATION FOR CLINICAL TRIALS FOR ABSORBED TETANUS VACCINE SUBMITTED (43K
- 2024-08-29
- VOLUNTARY ANNOUNCEMENT - PRE-APPLICATIONS FOR CLINICAL TRIALS FOR MRNA RSV AND MRNA SHINGLES/HERPES ZOSTER VACCINES OF AIM VACCINE SUBMITTED TO FDA
- 2024-08-29
- NOTICE OF BOARD MEETING
- 2024-08-19
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
- 2024-08-02
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
- 2024-07-02
- VOLUNTARY ANNOUNCEMENT - PRE-APPLICATIONS FOR CLINICAL TRIALS FOR TWO MRNA VACCINES OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND SHINGLES/HERPES ZOSTER OF AIM VACCINE SUBMITTED
- 2024-06-04
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
- 2024-06-04
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
- 2024-05-07
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
- 2024-05-07
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
- 2024-05-07
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
- 2024-05-07
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
- 2024-05-07
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
- 2024-05-07
- FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2024
- 2024-04-25
- NOTICE OF 2023 ANNUAL GENERAL MEETING
- 2024-04-25
- CIRCULAR OF 2023 ANNUAL GENERAL MEETING
- 2024-04-25
- VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
- 2024-04-18
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
- 2024-04-03
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
- 2024-04-03
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
- 2024-04-03
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
- 2024-04-03
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
- 2024-04-03
- VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE SUBMIT
- 2024-03-28
- VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR QUADRIVALENT INFLUENZA VIRUS VACCINE (MDCK CELLS) SUBMITTED
- 2024-03-28
- VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR NOVEL-PROCESS HIGHLY-EFFECTIVE HUMAN DIPLOID RABIES VACCINE SUBMITTED
- 2024-03-26
- NOTICE OF BOARD MEETING
- 2024-03-15
- VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR ABSORBED TETANUS VACCINE SUBMITTED
- 2024-03-04
- VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE II CLINICAL TRIAL OF TETRAVALENT MENINGOCOCCAL CONJUGATE VACCINE
- 2024-03-04
- PROFIT WARNING
- 2024-03-04
- VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE LAYOUT OF ITERATIVE RABIES VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES
- 2024-03-04
- VOLUNTARY ANNOUNCEMENT - COMPLETION OF THE LAYOUT OF ITERATIVE PNEUMONIA VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES
- 2024-03-04
- VOLUNTARY ANNOUNCEMENT - EXPECTED COMPLETION OF APPLICATION FOR MARKETING OF 13-VALENT PNEUMONIA CONJUGATE VACCINE, ITERATIVE SERUM-FREE RABIES VACCINE AND 23-VALENT PNEUMONIA POLYSACCHARIDE VACCINE IN 2024
- 2024-03-04
- VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR MARKETING REGISTRATION FOR 13-VALENT PNEUMONIA CONJUGATE VACCINE SUBMITTED
- 2024-03-01
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
- 2024-03-01
- (1) POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 29, 2024; (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND (3) APPOINTMENTS OF THE EXECUTIVE VICE-CHAIRMAN AND THE VICE-CHAIRMAN OF THE BOARD HAVING BECOME EFFECTIVE
- 2024-02-29
- (1) Notification Letter to Non-registered Shareholder and (2) Updated Arrangement of Electronic Dissemination of Corporate Communications
- 2024-02-08
- FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE 2024 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON FEBRUARY 29, 2024
- 2024-02-08
- PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND NOTICE OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING
- 2024-02-08
- (1) ELECTION OF THE EXECUTIVE VICE-CHAIRMAN AND THE VICE-CHAIRMAN OF THE BOARD; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
- 2024-02-08
- CLOSURE OF REGISTER OF MEMBERS
- 2024-02-07
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
- 2024-02-01
- VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
- 2024-01-10
- VOLUNTARY ANNOUNCEMENT - FURTHER CONTINUOUS INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
- 2024-01-02
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
- 2024-01-02
- VOLUNTARY ANNOUNCEMENT - FURTHER CONTINUOUS INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
- 2023-12-12
- VOLUNTARY ANNOUNCEMENT - FURTHER CONTINUOUS INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
- 2023-12-06
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
- 2023-12-04
- VOLUNTARY ANNOUNCEMENT - FURTHER CONTINUOUS INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
- 2023-11-30
- Articles of Association
- 2023-11-28
- (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING, THE DOMESTIC SHARE CLASS MEETING AND THE H SHARE CLASS MEETING HELD ON NOVEMBER 28, 2023; (2) ELECTION OF THE BOARD OF DIRECTORS IN THE SECOND SESSION; (3) ELECTION OF THE BOARD OF SUPERVISORS IN THE SECOND SESSION; (4) APPOINTMENT OF THE CHAIRMAN OF THE BOARD OF DIRECTORS AND THE BOARD OF SUPERVISORS IN THE SECOND SESSION; (5) CHANGE OF REGISTERED OFFICE; AND (6) AMENDMENTS TO THE ARTICLES OF ASSOCIATION
- 2023-11-28
- VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
- 2023-11-21
- VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF H SHARES BY THE CONTROLLING SHAREHOLDER
- 2023-11-17
- FORM OF PROXY OF HOLDERS OF H SHARES FOR USE AT THE 2023 THIRD H SHARE CLASS MEETING TO BE HELD ON NOVEMBER 28, 2023
- 2023-11-09
- FORM OF PROXY FOR HOLDERS OF H SHARES FOR THE 2023 SECOND EXTRAORDINARY GENERAL MEETING TO BE HELD ON NOVEMBER 28, 2023
- 2023-11-09
- NOTICE OF THE H SHARE CLASS MEETING
- 2023-11-09
- (1) PROPOSED RE-ELECTION OF DIRECTORS IN THE SECOND SESSION; (2) PROPOSED RE-ELECTION OF SHAREHOLDER REPRESENTATIVE SUPERVISORS IN THE SECOND SESSION; (3) PROPOSED CHANGE OF REGISTERED OFFICE; AND (4) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
- 2023-11-09
- CLOSURE OF REGISTER OF MEMBERS
- 2023-11-08
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
- 2023-11-03
- CHANGE IN USE OF IPO PROCEEDS
- 2023-10-23
- VOLUNTARY ANNOUNCEMENT - REGISTRATION APPLICATION FOR A SHARE LISTING TUTORING HAS BEEN FORMALLY ACCEPTED BY THE REGULATORY AUTHORITY
- 2023-10-17
- VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IS NEAR COMPLETION AND STATISTICAL UNBLINDING WILL COMMENCE SOON
- 2023-10-17
- VOLUNTARY ANNOUNCEMENT - SIGNING OF A SHARE LISTING TUTORING AGREEMENT AND FILING OF REGISTRATION APPLICATION FOR A SHARE LISTING TUTORING
- 2023-10-12
- INITIATION OF A SHARE LISTING PLAN
- 2023-10-08
- VOLUNTARY ANNOUNCEMENT - COMPLETION OF FULL COURSE OF VACCINATION IN SUBJECTS OF PHASE III CLINICAL TRIAL OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE
- 2023-10-08
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
- 2023-10-06
- VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL TRIAL OF SERUM-FREE RABIES VACCINE ACHIEVED SATISFACTORY PHASE RESULTS
- 2023-09-20
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
- 2023-09-05
- (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
- 2023-09-05
- VOLUNTARY ANNOUNCEMENT - THE APPROVAL FOR THE ISSUANCE OF UNLISTED RMB DENOMINATED ORDINARY SHARES FROM THE CSRC
- 2023-08-30
- VOLUNTARY ANNOUNCEMENT - INITIATION OF RANDOMIZED, BLINDED AND COMPARABLE VACCINE-CONTROLLED PHASE III CLINICAL TRIAL OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE
- 2023-08-29
- NOTICE OF BOARD MEETING
- 2023-08-17